New solution: A sugar solution injected into the knee may be a new method of treating osteo-arthritis

New solution: A sugar solution injected into the knee may be a new method of treating osteo-arthritis


  • การบำบัดแบบ Prolotherapy เกี่ยวข้องกับการฉีดสารละลายน้ำตาลที่หัวเข่า
  • การกระตุ้นนี้ปล่อยเซลล์ที่สามารถช่วยให้เกิดกระบวนการเยียวยาข้อเสื่อม

การใช้สารละลายน้ำตาลเดกซ์โทรส 10 -25 % ฉีดเข้าไปในข้อเข่าอาจเป็นวิธีใหม่ในการรักษาโรคข้อเสื่อม โดยน้ำตาลและน้ำจะช่วยลดอาการปวดและตึงโดยการกระตุ้นกลไกการซ่อมแซมร่างกายตามธรรมชาติ


การอักเสบนี้ไม่เพียงพอที่จะก่อให้เกิดอันตรายใด ๆ ที่รุนแรง แต่เพียงจะกระตุ้นการปล่อยเซลล์ที่สามารถช่วยในการรักษาความเสียหายบางส่วนที่เกิดจากโรค




Sweet release: The treatment, known as prolotherapy, is thought to work by triggering the release of cells that repair damaged ligaments in the knee

Sweet release: The treatment, known as prolotherapy, is thought to work by triggering the release of cells that repair damaged ligaments in the knee

A dose of sugar can ease the pain of creaky knees by releasing cells that repair damaged ligaments

  • Prolotherapy involves injecting a sugar solution into the knee
  • This stimulates the release of cells that can help the healing process


PUBLISHED: 21:11 GMT, 8 July 2013

A sugar solution injected into the knee could be a new way to treat osteo-arthritis. Research suggests the sugar and water mixture reduces pain and stiffness by stimulating the body’s natural repair mechanisms.

The sweet solution works by acting as a mild irritant inside the joint, triggering low-level inflammation.

This inflammation is not enough to cause any severe harm, but is sufficient to stimulate the release of cells that can help to heal some of the damage caused by the disease.

Doctors use a solution containing water and between 10 and 25 per cent dextrose, a type of sugar.

They use dextrose because it is cheap, readily available and safe – causing only mild irritation inside the knee joint. The treatment, known as prolotherapy, is thought to work by triggering the release of fibroblasts, cells that build and maintain connective tissue such as ligaments.

The fibroblasts repair damaged ligaments in the knee, making it more stable and relieving discomfort.

In a recent study at the University of Wisconsin in the U.S., researchers recruited 90 men and women with painful knee osteoarthritis and split them into three groups.

One group received three separate sugar jabs, each one four weeks apart, and another had injections of a salt water solution.

The last group did not have any injections but instead followed an at-home exercise regimen designed to alleviate some of the pain and discomfort.

Each volunteer was monitored using a scoring  system, called the Western Ontario McMaster University Osteo-arthritis Index, to measure the severity of the condition. The 12-minute test uses a 100-point scale  and includes questions on how easy it is to use the stairs, get in and out of a car or put on a pair of socks.

The results, published in the Annals of Family Medicine, showed that one year after the treatment began, the sugar jab group had the biggest improvement in symptoms and were better able to carry out everyday activities.

On average, the sugar group improved by a total of 16 points, compared with five points for salt water jabs and seven for the exercise group. The team are unsure why salt water was not as effective as sugar.

This technique is also being tried in other conditions such as chronic back pain and tennis elbow.

Commenting on the approach, Professor Alan Silman, medical director of Arthritis Research UK, said: ‘Though some “irritant” treatments can be effective, much more work is needed before a treatment based on sugar solution could be recommended to patients.’

Meanwhile, scientists have designed a special glove that may ease the pain of hand arthritis.

Around 130 people who suffer from rheumatoid and osteoarthritis are being treated with the compression glove in a new clinical trial.

The gloves are made from a special fabric that when stretched (when it is worn) puts pressure on the hand and joints.

It’s thought that the pressure might trigger mild inflammation, which, unlike severe inflammation, eases pain although it is not clear why.

In the year-long trial, due to start in September and being  co-ordinated by the University of Salford, patients will be given the compression gloves as part of their usual care.

They will be assessed before and after for pain and stiffness.

SOURCE: www.dailymail.co.uk

การรับประทานน้ำมันปลาและแอสไพรินร่วมกันจะช่วยบรรเทาความเจ็บป่วยเรื้อรัง เช่น โรคข้อ

Scientists have discovered that taking fish oil and aspirin together could help to ease beat chronic illnesses such as arthritis

Scientists have discovered that taking fish oil and aspirin together could help to ease beat chronic illnesses such as arthritis


นักวิทยาศาสตร์พบว่าการรับประทานน้ำมันปลาและแอสไพรินร่วมกันจะช่วยบรรเทาความเจ็บป่วยเรื้อรัง เช่น โรคข้ออักเสบ


Fish oils have long been heralded for their beneficial effects on the brain, bones and heart

Fish oils have long been heralded for their beneficial effects on the brain, bones and heart

The cure for arthritis? Fish oil AND aspirin, according to a breakthrough discovery

  • The two work together to combat inflammation that causes pain of arthritis


PUBLISHED: 18:17 GMT, 22 February 2013

Fish oil and aspirin could be the key to beating a host of devastating chronic diseases, according to new research.

Researchers from the Brigham and Women’s Hospital and Harvard Medical School in Boston found that the two work together to combat the inflammation responsible for a host of illnesses, including heart disease, cancer, arthritis and Alzheimer’s.

Both aspirin and omega-3 fatty acids from fish are known to have an anti-inflammatory effect on their own, but the research shows that when taken together they can control the overactive immune responses associated with long-term illnesses.

Inflammation is the body’s natural response to injury and foreign bodies.

When something harmful or irritating affects a part of the body, there is a biological response to try to remove it, and the symptoms of inflammation show that the body is trying to heal itself.

But if the person suffering has a high-fat diet, too much body fat or is a smoker, for example, the may not be a break from the irritants, so the immune system can lose control, increasing risk of disease.

Long-term, inflammation can become chronic which can then damage heart valves and brain cells, causing strokes and promoting resistance to insulin, which leads to diabetes.

It is also associated with the development of cancer.

Aspirin is used by millions of people to keep heart attacks and strokes at bay. The drug is used to thin the blood, which reduces the risk of clots.

It works by helping to trigger the production of molecules called resolvins that are made naturally by the body from omega-3 fatty acids.

These resolvins ‘resolve’, the inflammation that underlies the health conditions which blight the lives of millions.

Omega-3 is found in oily fish, particularly salmon and sardines, as well as chicken, nuts, kale and spinach as well as vegetable oils.

One resolvin called D3 was found to have an especially long-lasting anti-inflammatory effect.

The researchers said: ‘In this report, we found that one resolvin, termed D3 and from omega-3 fatty acid, persists longer at sites of inflammation than either resolvin D1 or resolvin D2 in the nat­ural resolution of inflammation in mice.

‘This finding suggests that this late resolution phase resolvin D3 might display unique properties in fighting uncontrolled inflammation.’

The researchers also confirmed that aspirin triggered the production of a longer-acting form of resolvin D3 through a different pathway.

The team were able to produce a pure form of both resolvin D3 and aspirin-triggered resolvin D3.

When administered to human cells, both of these showed highly potent anti-inflammatory actions.

The research was published in the journal Chemistry & Biology.

SOURCE: dailymail.co.uk

ถูกแดดกันโรคข้ออักเสบ อาบมากไปเข้าใกล้มะเร็ง

thairath130211_001แพทย์ผู้เชี่ยวชาญแนะนำว่า คนเราควรหาถิ่นฐานที่อยู่ในที่ซึ่งมีแสงแดดส่อง เพราะมันจะช่วยป้องกันไม่ให้เป็นโรคข้ออักเสบง่าย ๆ

วารสารการแพทย์ “โรคข้ออักเสบแห่งอังกฤษ” แจ้งว่า นักวิจัยของโรงเรียนสาธารณสุขฮาร์วาร์ด ได้ศึกษากับผู้หญิงไม่ต่ำกว่า 2 แสนคน เพื่อหาความเกี่ยวพันของแสงแดดกับโรคข้ออักเสบ เพราะเชื่อว่าวิตามินดีในแสงแดดอาจจะให้คุณ ช่วยปกป้องร่างกายได้ แต่บอกไว้ก่อนว่า ไม่ควรจะไปตากแดดหัวแดงตลอดทั้งวัน เพราะอาจจะล่อแหลมกับการเป็นมะเร็งผิวหนังได้

โรคข้ออักเสบ มักจะเป็นกันมากในหมู่สตรี เกิดจากระบบภูมิคุ้มโรคของตัวเองกลับหันไปทำร้ายข้อต่อ ทำให้เกิดอาการเจ็บปวดอย่างรุนแรง.

ที่มา :ไทยรัฐ 11 กุมภาพันธ์ 2556


Related Article:


Women regularly exposed to sunlight reduced their risk of developing rheumatoid arthritis by a fifth

Women regularly exposed to sunlight reduced their risk of developing rheumatoid arthritis by a fifth

Soaking up the sun can reduce the risk of rheumatoid arthritis

  • Women regularly exposed to sunlight reduced their risk of developing the condition by a fifth
  • But using sun creams or covering up to avoid the sun could lessen the protective effects



PUBLISHED: 00:57 GMT, 5 February 2013

Soaking up the sun may reduce a woman’s risk of rheumatoid arthritis.

New research has shown that those regularly exposed to sunlight reduced their risk of developing the condition by a fifth.

But using sun creams or covering up to avoid the sun could lessen the protective effects.

And in younger women who have heeded the calls to protect themselves from the harmful effects of the sun, the effect of UVB exposure was less evident.

Rheumatoid arthritis is an autoimmune disease that causes inflammation in joints and the main symptoms are joint pain and swelling. The condition is the second most common form of arthritis in the UK.


There are an estimated 300,000 sufferers in the UK with women three times more likely to suffer from the disease than men.

The long term study looked at participants in two phases of the US Nurses’ Health Study, the first of which has tracked the health of more than 120,000 nurses since 1976, when they were aged between 30 and 55, until 2008.

The second phase tracked the health of a further 115,500 nurses since 1989, when they were aged between 25 and 42, until 2009.

Rather than simply relying on geography to quantify likely levels of UVB exposure, the researchers used a more sensitive assessment, known as UV-B flux, which is a composite measure of UVB radiation, based on latitude, altitude, and cloud cover.

Exposure was then estimated according to where they lived in the US and ranged from an annual average of 93 in Alaska and Oregon to 196 in Hawaii and Arizona where they get the most sunshine.

Likely estimates of UV exposure at birth and by the age of 15 were also included.

Over the period, 1,314 women developed rheumatoid arthritis.

Among nurses in the first phase, higher cumulative exposure to UVB was associated with a reduced risk of developing the disease.

Those with the highest levels of exposure were a fifth less likely to develop rheumatoid arthritis than those with the least.

This confirms the findings of other studies, showing a link between geography and the risk of rheumatoid arthritis as well as other autoimmune conditions, including type 1 diabetes, inflammatory bowel disease, and multiple sclerosis.

But no such association for UV-B exposure was found among women in the second phase because these women were younger than those in the first study, and so might have been more aware about the potential hazards of acquiring a tan.

The authors added: ‘Differences in sun protective behaviours, for example greater use of sun block in younger generations, may explain the disparate results’.

But they conclude: ‘Our study adds to the growing evidence that exposure to UV-B light is associated with decreased risk of rheumatoid arthritis. The mechanisms are not yet understood, but could be mediated by the cutaneous production of vitamin D and attenuated by use of sunscreen or sun avoidant behaviour.’

The findings are published online in the Annals of the Rheumatic Diseases.

SOURCE: dailymail.co.uk


Do-si-do: Dancing once a week could relieve the pain of arthritis

การออกกำลังกาย เช่น ชี่กง พิลาเตส โยคะ เต้นรำ สามารถลดความเจ็บปวดจากโรคข้ออักเสบได้ นอกจากนี้ยังช่วยให้เกิดความสมดุล สุขภาพจิตดี การเคลื่อนไหวคล่องตัว และสนุกกับการใช้ชีวิต

How dancing just once a week could relieve the pain of arthritis

  • Just over half of arthritis sufferers who took part in exercise programme experienced pain relief
  • Exercises included dancing, yoga and Pilates


PUBLISHED: 17:24 GMT, 13 November 2012

Having a waltz around the room or enjoying a yoga class can work wonders for millions of people suffering from arthritis, say researchers.

A study found hospital-based exercise programs such as Pilates, yoga or dance fitness can relieve the pain of the disease.

American scientists studied at the effectiveness of exercise programmes run by the Hospital for Special Surgery in New York City.

They found the weekly programmes significantly improved enjoyment of life and balance, and decreased pain and the severity and frequency of falls.

Sandra Goldsmith, director of the Public and Patient Education Department at HSS said: ‘When participants were asked to report their level of pain severity, there were statistically significant reductions in pain from pre- to post-test.

‘Pain is a huge factor in quality of life. If we can offer classes that help to reduce pain, that is a good thing.’

Researchers evaluated the effectiveness of the exercise programs, which included weekly classes of Tai Chi, yoga, mat and chair Pilates and dance fitness on 200 participants.

Surveys were administered before and after the exercise which included measures of self-reported pain, balance, falls and level of physical activity.

A pain intensity scale was used to quantify intensity of muscle or joint pain.

The team also measured pain interference on aspects of quality of life, including general activity, mood, walking ability, sleep, work, and enjoyment of life.

Roughly 53 per cent indicated that they experienced pain relief as a result of participating.

There was a 54 per cent improvement in general activity, mood, walking ability, sleep, normal work, and enjoyment of life.

Fewer respondents reported falling from pre- to post-test and fewer sustained injuries that required hospitalisation.

Dr Linda Russell, a rheumatologist, points out that the classes are low cost for patients.

‘We like to get all of our patients involved in exercise.

‘Patients benefit from supervised exercise programmes with regard to their overall sense of well-being and pain due to their arthritis.’

Osteoarthritis is a leading cause of disability in the UK, affecting around 8.5million adults.

Weight has a large influence on the prevalence of arthritis with nearly 30 per cent of obese adults suffering.

The latest study was presented at the recent American College of Rheumatology/Association of Rheumatology Health Professionals annual meeting.

SOURCE: dailymail.co.uk

Immunologists find a molecule that puts the brakes on inflammation

Christopher Hunter and Aisling O’Hara Hall

(Medical Xpress) September 28, 2012—We couldn’t live without our immune systems, always tuned to detect and eradicate invading pathogens and particles. But sometimes the immune response goes overboard, triggering autoimmune diseases like lupus, asthma or inflammatory bowel disease.

A new study led by University of Pennsylvania researchers has now identified a crucial signaling molecule involved in counterbalancing the immune system attack.

“The immune response is like driving a car,” said Christopher Hunter, professor and chair in the Department of Pathobiology in Penn’s School of Veterinary Medicine. “You hit the accelerator and develop this response that’s required to protect you from a pathogen, but, unless you have a brake to guide the response, then you’ll just careen off the road and die because you can’t control the speed of the response.”

The research to characterize this immune system “brake” was led by Hunter and Aisling O’Hara Hall, a doctoral candidate in the Immunology Graduate Group. Additional Penn collaborators included scientists from the Penn Genome Frontiers Institute’s Department of Biology and the Perelman School of Medicine’s Department of Medicine.Researchers from Merck Research Laboratories, the National Institute of Allergy and Infectious Disease, Harvard Medical School and Janssen Research and Development also contributed to the work, which was published in the journal Immunity.

“Healthy people have these cells—you have them, I have them—that are called Tregs,” or regulatory T cells, Hunter said. “If you don’t have them you develop spontaneous inflammation and disease.”

Different forms of regulatory T cells operate as the brakes on various kinds of inflammation, but, until now, scientists hadn’t been certain of how these Tregs became specialized to do their particular jobs.

Hall, Hunter and colleagues decided to follow up on a molecule called IL-27. Scientists used to think IL-27 played a role in causing inflammation, but, in 2005, a team of Penn researchers, including Hunter, found the opposite; it was actually involved in suppressing inflammation. Thus, when mice that lack IL-27 are challenged with the parasite Toxoplasma gondii, they develop overwhelming inflammation. ”

We never worked out how it did that, but it was a paradigm change at the time,” Hunter said.

In the new study, the researchers delved deeper into IL-27’s role. They found that exposing regulatory T cells to IL-27 promoted their ability to suppress a particular type of inflammation. The Penn-led team also demonstrated that they could rescue infected IL-27-deficient mice by giving them a transfusion of regulatory T cells. This finding suggests that IL-27 is required to produce the Treg cells that normally keep inflammatory responses in check during infection.

“Very surprisingly, we were able to show that the Tregs could ameliorate the pathology in this system,” Hall said. “We don’t think this is the only mechanism by which IL-27 limits immune pathology, but it sheds light on one mechanism by which it could be functioning.”

Further experiments showed that Tregs express a different suite of genes in the presence of IL-27 as compared to another molecule that has been implicated in this process, interferon gamma, or IFN-γ. The researchers’ findings indicate that the two molecules have division of labor when it comes to suppressing inflammation: IL-27 seems to be important in helping control inflammation at the site of inflammation, whereas IFN-γ appears more significant in the peripheral tissues.

“At the site of inflammation, where you’re getting your pathology, that’s where IL- 27 is important,” Hall said.

With a new understanding of how IL-27 may cause a class of Tregs to become specialized inflammation fighters, researchers have a new target for ameliorating the unwanted inflammation associated with all kinds of autoimmune conditions.

“Now we have a molecular signature that may be relevant in inflammatory bowel disease, in multiple sclerosis, in colitis and Crohn’s disease, in rheumatoid arthritis, in lupus,” Hunter said.

Next on tap, the team plans to study IL-27 in the context of asthma , lupus and arthritis.

More information: dx.doi.org/10.1016… .2012.06.014 J
Journal reference: Immunity
Provided by University of Pennsylvania

SOURCE: medicalxpress.com

Delivery System for Gene Therapy May Help Treat Arthritis

ScienceDaily (May 15, 2012) — A DNA-covered submicroscopic bead used to deliver genes or drugs directly into cells to treat disease appears to have therapeutic value just by showing up, researchers report.

Within a few hours of injecting empty-handed DNA nanoparticles, Georgia Health Sciences University researchers were surprised to see increased expression of an enzyme that calms the immune response.

In an animal model of rheumatoid arthritis, the enhanced expression of indoleomine 2,3 dioxygenase, or IDO, significantly reduced the hallmark limb joint swelling and inflammation of this debilitating autoimmune disease, researchers report in the study featured on the cover of The Journal of Immunology.

“It’s like pouring water on a fire,” said Dr. Andrew L. Mellor, Director of the GHSU’s Medical College of Georgia Immunotherapy Center and the study’s corresponding author. “The fire is burning down the house, which in this case is the tissue normally required for your joints to work smoothly,” Mellor said of the immune system’s inexplicable attack on bone-cushioning cartilage. “When IDO levels are high, there is more water to control the fire.”

Several delivery systems are used for gene therapy, which is used to treat conditions including cancer, HIV infection and Parkinson’s disease. The new findings suggest the DNA nanoparticle technique has value as well for autoimmune diseases such as arthritis, type 1 diabetes and lupus. “We want to induce IDO because it protects healthy tissue from destruction by the immune system,” Mellor said.

The researchers were exploring IDO’s autoimmune treatment potential by inserting the human IDO gene into DNA nanoparticles. They hoped to enhance IDO expression in their arthritis model when Dr. Lei Huang, Assistant Research Scientist and the paper’s first author, serendipitously found that the DNA nanoparticle itself produced the desired result. Exactly how and why is still being pursued. Early evidence suggests that immune cells called phagocytes, white blood cells that gobble up undesirables like bacteria and dying cells, start making more IDO in response to the DNA nanoparticle’s arrival. “Phagocytes eat it and respond quickly to it and the effect we measure is IDO,” Mellor said.

Dr. Tracy L. McGaha, GHSU immunologist and a co-author on the current study, recently discovered that similar cells also prevented development of systemic lupus erythematosus in mice.

Follow-up studies include documenting all cells that respond by producing more IDO. GHSU researchers already are working with biopolymer experts at the Massachusetts Institute of Technology, the University of California, Berkeley and the Georgia Institute of Technology to identify the optimal polymer.

The polymer used in the study is not biodegradable so the researchers need one that will eventually safely degrade in the body. Ideally, they’d also like it to target specific cells, such as those near inflamed joints, to minimize any potential ill effects.

“It’s like a bead and you wrap the DNA around it,” Mellor said of the polymer. While the DNA does not have to carry anything to get the desired response in this case, DNA itself is essential to make cells express IDO. To ensure that IDO expression was responsible for the improvements, they also performed experiments in mice given an IDO inhibitor in their drinking water and in mice genetically altered to not express IDO. “Without access to the IDO pathway, the therapy no longer works,” Mellor said.

Drs. Andrew Mellor and David Munn reported in 1998 in the journal Science that the fetus expresses IDO to help avoid rejection by the mother’s immune system. Subsequent studies have shown tumors also use IDO for protection and clinical trials are studying the tumor-fighting potential of an IDO inhibitor. On the flip side, there is evidence that increasing IDO expression can protect transplanted organs and counter autoimmune disease.

Mellor is the Bradley-Turner and Georgia Research Alliance Eminent Scholar in Molecular Immunogenetics at MCG. The research was funded by the Carlos and Marguerite Mason Trust and the National Institutes of Health and a patent is pending on the findings.

Story Source:

The above story is reprinted from materials provided byGeorgia Health Sciences University. The original article was written by Toni Baker.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

  1. L. Huang, H. P. Lemos, L. Li, M. Li, P. R. Chandler, B. Baban, T. L. McGaha, B. Ravishankar, J. R. Lee, D. H. Munn, A. L. Mellor. Engineering DNA Nanoparticles as Immunomodulatory Reagents that Activate Regulatory T CellsThe Journal of Immunology, 2012; 188 (10): 4913 DOI: 10.4049/jimmunol.1103668
Drs. Andrew L. Mellor (left) and Lei Huang at Georgia Health Sciences University have shown a system called DNA nanoparticles, used to deliver genes or drugs directly into cells to treat a variety of diseases, may help arthritis without delivering anything. (Credit: Image courtesy of Georgia Health Sciences University)

Data from: sciencedaily.com

Arthritis sufferers have to wait THREE YEARS to be diagnosed condemning them to ‘unbearable pain’

Arthritis sufferers have to wait THREE YEARS to be diagnosed condemning them to ‘unbearable pain’
PUBLISHED: 00:17 GMT, 9 May 2012

More than a quarter of arthritis sufferers have to visit their GP at least three times to get a diagnosis, a report reveals.

Patients with osteoarthritis, the most common form, wait an average of nearly three years to be diagnosed and referred for treatment.

The number of Britons suffering from the crippling condition is expected to double over the next 20 years due to the ageing population and higher levels of obesity.

There are an estimated 8.5million people with osteoarthritis but by 2030 this will have reached 17million, according to the report by Arthritis Care.

The charity is concerned that many patients are enduring ‘unbearable’ pain, seeing it as an inevitable part of old age but wrongly believing nothing can be done about it.

A survey of 2,000 patients carried out on behalf of the charity found that nearly three-quarters (71 per cent) are in constant pain.

For one in eight, the symptoms severely restrict their daily lives, preventing them from walking or going upstairs.

On average the patients waited 2.8 years from noticing symptoms to being given a diagnosis by their family doctor.

Judith Brodie, chief executive of the charity, blamed the delay on patients’ reluctance to seek help and a lack of awareness among GPs.

She said: ‘Many people, particularly the elderly, are very stoical about pain. They may well think nothing can be done.

‘There’s an issue of awareness among GPs and in primary care about osteoarthritis. It could be a lot better.

‘But our message is that there is something you can do. A lot of people are really denying themselves a good old age.’ The poll also found that patients spent an average of £500 a year of their own money on treatment and travel costs.

A third said the condition had forced them to retire early or substantially reduce the numbers of hours they worked.

Osteoarthritis, which normally develops after the age of 50, causes damage to the cartilage, the smooth tissue covering joint surfaces, which leads to pain in the hips, knees, hands and feet.
It is more common among the overweight.

There is no cure but the pain can be substantially reduced through exercise, weight loss and some complementary therapies such as acupuncture.

Many patients take regular painkillers such as paracetamol or non-steroidal anti-inflammatory drugs.

Experts warn that the surge in the numbers of patients will place huge strain on the health service.

Already the condition is estimated to cost the economy £3.2billion in lost working time.

About 140,000 hip and knee replacements a year are performed on the NHS because of osteoarthritis at a cost of at least £700million.

Philip Conaghan, professor of musculoskeletal medicine at the University of Leeds, said: ‘Britain is facing a tsunami of pain due to osteoarthritis as the number of people over 50 increases dramatically and obesity levels continue to rise.

‘Action is needed immediately. We have to bust this myth that painful joints are an inevitable part of getting older that we have to put up with.’

Data from: dailymail.co.uk




Read more…


New injection could offer hope to millions of arthritis sufferers

  • Molecule found to encourage cartilage regeneration
  • Could form the basis of new drug-based therapy


PUBLISHED: 10:03 GMT, 6 April 2012 | UPDATED: 14:51 GMT, 6 April 2012

An injection could help cure the crippling symptoms of arthritis, say scientists.

A study found that a molecule, called kartogenin, encourages damaged cartilage to regenerate.

It is now hoped that the substance could form the basis of a new drug-based therapy, targeting the degenerative joint and bone disease which causes cartilage to wear away.

In the UK, arthritis affects over 9 million people, the most common forms being osteoarthritis and rheumatoid arthritis

Main symptoms of arthritis include pain, stiffness and restricted movement in the joints, and in the UK it affects more than 9 million people.

Currently these is no cure for the condition, only anti-inflammatory painkillers to relieve symptoms, and in severe cases, costly joint replacements are advised.

Commenting on the latest study researchers at the Genomics Institute of the Novartis Research Foundation in San Diego and Scripps Research Institute in La Jolla, California said: ‘This may ultimately lead to a stem-cell based therapy for osteoarthritis.’

While Dr Kristen Johnson, added: ‘We’re excited about the biology because it’s a new way of targeting the stem cells.’

It is thought that kartogenin would be administered via injection to the areas affected (stock picture) During the study, published in the journal Science, 22,000 drug-like molecules were tested using a robotic screen, applying each one to bone marrow stem cells.

When kartogenin was administered to mice with osteoarthritis-like symptoms, it prompted stem cells to change into cartilage cells.
A patent has already been filed, however more work is needed to understand exactly how the molecule works.

Judith Brodie, chief executive of Arthritis Care, said: ‘We are delighted with any potential breakthrough for people with arthritis.

‘We hear every day about the pain suffered by people with osteoarthritis and, although treatments are some years away, we look forward to anything that will help relieve their condition.’

The most common forms of arthritis are osteoarthritis and rheumatoid arthritis.

Around eight million people in Britain suffer from osteoarthritis and 140,000 hip and knee replacements are performed on the NHS as a result of the illness, at a cost of more than £1 billion.

Data from: dailymail

‘Mindfulness’ exercises help curb stress and fatigue associated with arthritis

การฝึก “เจริญสติ” ช่วยลดความเครียดและความเหนื่อยล้าที่เกี่ยวข้องกับโรคข้ออักเสบอักเสบต่าง ๆ  เช่น โรคขออักเสบรูมาตอยด (Rheumatoid Arthritis), โรคข้อสันหลังอักเสบติดยึด (Ankylosing Spondylitis) , โรคขออักเสบสะเก็ดเงิน. (Psoriatic Arthritis)

“Mindfulness” exercises, which focus on experiencing the present moment, no matter how difficult, can help curb the stress and fatigue associated with painful rheumatoid joint disease, indicates a small study published online in the Annals of Rheumatic Diseases.

The authors base their findings on 73 patients between the ages of 20 and 70, all of whom had had painful joint disease, caused by rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis for at least a year.
Half of them were randomly allocated to scheduled “mindfulness” exercises, which took place in 10 group sessions over a period of 15 weeks, plus a booster session around six months after the course had completed.

The sessions, which were facilitated by healthcare professionals trained in mindfulness techniques, addressed particular topics, such as recognising individual limitations, and strong emotions, such as anger, joy, and sorrow.
The exercises, which were part of the Vitality Training Programme of VTP, encouraged participants to become aware of, and deliberately concentrate on their feelings, thoughts and bodily experiences, including pain, without judging or trying to avoid them.

Participants were also given creative exercises, such as guided imagery, music and drawing, and shared their experiences with other members of the group.

The rest of the volunteers randomly allocated to the comparison group were given standard care plus a CD containing similar exercises for use at home, as and when they wanted.

Stress levels, coping abilities, and symptom control, including pain and fatigue, were assessed, using validated scores, immediately after all 10 sessions had finished, and again 12 months later.

In total, 67 participants completed all the assessments. These showed no differences in pain levels, disease activity or the ability to talk about feelings.
But there were significant differences in levels of stress and fatigue.
The number of participants with a high stress score of above 23 in the GHQ-20 questionnaire fell from 13 at the start of the study to two, just 12 months after the sessions had finished. Comparable figures in the comparison group were 10 and eight, respectively.

There was, however, a tangible fall in measured levels of fatigue in the intervention group: no such change was evident in the comparison group.
There have been previous attempts to use psychological and educational tactics to help people with arthritis cope better with the distressing aspects of the disease, but they have tended to be short term, say the authors.
The lasting improvements found with the VTP course “indicate that the participants may have incorporated some mindfulness strategies into their daily lives and that these strategies have strengthened their ability to respond to their stressful experience in a more flexible way,” they say.

The authors emphasise that while the treatment of rheumatoid arthritis has improved greatly, it is less effective in those with more established disease, and that ultimately the disease can only be partly controlled, forcing many patients to make very demanding lifestyle changes.

“There is therefore a need for complementary interventions that enhance individuals’ health-promoting resources and help them adjust to their disease,” they conclude.

More information: To be published at http://ard.bmj.com

Data from: medicalxpress.com


Related links:

Web link Buddhist meditation retreats